Novo Nordisk hypertension candidate ocedurenone fails in phase 3

Novo Nordisk (NVO) said that ocedurenone, under investigation for uncontrolled hypertension in chronic kidney disease patients, missed its primary endpoint in a phase 3 trial.
That endpoint was change in systolic blood pressure from baseline to week 12.
As a result, the Danish pharma is ending the trial and will also incur an impairment charge of ~DKK 5.7B (~$816.5M). This will lead to an estimated negative impact of around six percentage points on operating profit growth at constant exchange rates this year compared to what was outlined in Novo’s Q1 financial report.